$27.00
At close: Apr 30 EDT
$26.99
-0.01-0.04%
Pre-Market: 6:51 PM EDT
Comments
Loading...
Structure Therapeutics Analyst Ratings and Price Targets | NASDAQ:GPCR | Benzinga
Structure Therapeutics Inc has a consensus price target of $76.5 based on the ratings of 13 analysts. The high is $118 issued by Morgan Stanley on September 23, 2024. The low is $40 issued by BMO Capital on February 28, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Citizens Capital Markets, and Stifel on April 22, 2025, February 28, 2025, and January 8, 2025, respectively. With an average price target of $72.33 between HC Wainwright & Co., Citizens Capital Markets, and Stifel, there's an implied 168.00% upside for Structure Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citizens Capital Markets
Stifel
JMP Securities
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Structure Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/22/2025 | Buy Now | 196.41% | HC Wainwright & Co. | Andrew Fein57% | $80 → $80 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 222.34% | Citizens Capital Markets | Jonathan Wolleben68% | $91 → $87 | Maintains | Market Outperform | Get Alert |
| 02/28/2025 | Buy Now | — | William Blair | Andy Hsieh31% | — | Initiates | → Outperform | Get Alert |
| 01/08/2025 | Buy Now | 85.25% | Stifel | Annabel Samimy67% | → $50 | Initiates | → Buy | Get Alert |
| 12/20/2024 | Buy Now | 196.41% | HC Wainwright & Co. | Andrew Fein57% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 196.41% | HC Wainwright & Co. | Andrew Fein57% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 237.16% | JMP Securities | Jonathan Wolleben68% | $91 → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/04/2024 | Buy Now | 196.41% | HC Wainwright & Co. | Andrew Fein57% | → $80 | Initiates | → Buy | Get Alert |
| 09/23/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/23/2024 | Buy Now | 337.2% | Morgan Stanley | Terence Flynn67% | → $118 | Initiates | → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 218.64% | JMP Securities | Jonathan Wolleben68% | $91 → $86 | Maintains | Market Outperform | Get Alert |
| 07/01/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/07/2024 | Buy Now | 270.51% | BMO Capital | Evan David Seigerman49% | $83 → $100 | Maintains | Outperform | Get Alert |
| 06/03/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/21/2024 | Buy Now | 140.83% | JP Morgan | Hardik Parikh10% | → $65 | Initiates | → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 237.16% | JMP Securities | Jonathan Wolleben68% | $91 → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/03/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 04/09/2024 | Buy Now | 140.83% | Cantor Fitzgerald | Prakhar Agrawal38% | → $65 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 237.16% | JMP Securities | Jonathan Wolleben68% | $91 → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/20/2023 | Buy Now | 237.16% | JMP Securities | Jonathan Wolleben68% | → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/15/2023 | Buy Now | 237.16% | JMP Securities | Jonathan Wolleben68% | $90 → $91 | Maintains | Market Outperform | Get Alert |
| 10/27/2023 | Buy Now | 244.57% | Piper Sandler | Yasmeen Rahimi57% | $58 → $93 | Maintains | Overweight | Get Alert |
| 10/26/2023 | Buy Now | 244.57% | Piper Sandler | Yasmeen Rahimi57% | $58 → $93 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 233.46% | JMP Securities | Jonathan Wolleben68% | → $90 | Initiates | → Market Outperform | Get Alert |
| 10/03/2023 | Buy Now | 207.52% | BMO Capital | Evan David Seigerman49% | $40 → $83 | Maintains | Outperform | Get Alert |
| 09/29/2023 | Buy Now | 192.7% | Jefferies | Chris Howerton63% | $50 → $79 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | 114.89% | Piper Sandler | Yasmeen Rahimi57% | → $58 | Initiates | → Overweight | Get Alert |
| 02/28/2023 | Buy Now | 85.25% | Guggenheim | Seamus Fernandez60% | → $50 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 48.2% | BMO Capital | Evan Seigerman64% | → $40 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | 25.97% | Jefferies | Chris Howerton63% | → $34 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Structure Therapeutics (GPCR) stock?
The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by HC Wainwright & Co. on April 22, 2025. The analyst firm set a price target for $80.00 expecting GPCR to rise to within 12 months (a possible 196.41% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Structure Therapeutics (GPCR)?
The latest analyst rating for Structure Therapeutics (NASDAQ:GPCR) was provided by HC Wainwright & Co., and Structure Therapeutics maintained their buy rating.
When was the last upgrade for Structure Therapeutics (GPCR)?
There is no last upgrade for Structure Therapeutics
When was the last downgrade for Structure Therapeutics (GPCR)?
There is no last downgrade for Structure Therapeutics.
When is the next analyst rating going to be posted or updated for Structure Therapeutics (GPCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Structure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Structure Therapeutics was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.
Is the Analyst Rating Structure Therapeutics (GPCR) correct?
While ratings are subjective and will change, the latest Structure Therapeutics (GPCR) rating was a maintained with a price target of $80.00 to $80.00. The current price Structure Therapeutics (GPCR) is trading at is $26.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
